Dr Grisham on the Efficacy of Avutometinib Plus Defactinib in Gynecologic Mesonephric Cancer

Rachel N. Grisham, MD, discusses the efficacy of avutometinib plus defactinib in patients with advanced or recurrent gynecologic mesonephric cancer.

“What we showed is that, in the first 13 patients [with stage I disease] accrued to the study, there were 2 confirmed and an additional 2 unconfirmed partial responses exceeding the predefined threshold.”

Rachel N. Grisham, MD, an associate attending physician at Memorial Sloan Kettering Cancer Center; section head of Ovarian Cancer; and director of Gynecologic Medical Oncology, at Memorial Sloan Kettering Cancer Center Westchester, discusses interim results from a phase 2 study (NCT05787561), which evaluated avutometinib (VS-6766) plus defactinib (VS-6063) in patients with advanced or recurrent gynecologic mesonephric cancer.